CN1191139A - 含有促性腺素的液体制剂 - Google Patents
含有促性腺素的液体制剂 Download PDFInfo
- Publication number
- CN1191139A CN1191139A CN98104149A CN98104149A CN1191139A CN 1191139 A CN1191139 A CN 1191139A CN 98104149 A CN98104149 A CN 98104149A CN 98104149 A CN98104149 A CN 98104149A CN 1191139 A CN1191139 A CN 1191139A
- Authority
- CN
- China
- Prior art keywords
- gonadotropin
- preparation
- liquid preparation
- liquid
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000006771 Gonadotropins Human genes 0.000 title claims abstract description 91
- 108010086677 Gonadotropins Proteins 0.000 title claims abstract description 91
- 239000002622 gonadotropin Substances 0.000 title claims abstract description 91
- 239000007788 liquid Substances 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 238000009472 formulation Methods 0.000 title abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 96
- 229930182817 methionine Natural products 0.000 claims abstract description 20
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 18
- 229930006000 Sucrose Natural products 0.000 claims abstract description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 15
- 239000005720 sucrose Substances 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 12
- -1 sucrose Chemical class 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 11
- 239000001509 sodium citrate Substances 0.000 claims abstract description 9
- 239000007864 aqueous solution Substances 0.000 claims abstract description 8
- 150000002840 non-reducing disaccharides Chemical class 0.000 claims abstract description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 35
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 35
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 34
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 17
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 claims description 4
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000012669 liquid formulation Substances 0.000 claims description 4
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 3
- 208000000509 infertility Diseases 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 231100000535 infertility Toxicity 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 abstract description 13
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 150000003568 thioethers Chemical class 0.000 abstract 2
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 230000003019 stabilising effect Effects 0.000 abstract 1
- 235000006109 methionine Nutrition 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 229940068977 polysorbate 20 Drugs 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 229940015047 chorionic gonadotropin Drugs 0.000 description 5
- 230000008521 reorganization Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 108010057021 Menotropins Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 3
- 125000001118 alkylidene group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 239000004470 DL Methionine Substances 0.000 description 2
- 102000008175 FSH Receptors Human genes 0.000 description 2
- 108010060374 FSH Receptors Proteins 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960000874 thyrotropin Drugs 0.000 description 2
- 230000001748 thyrotropin Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010066058 beta Subunit Luteinizing Hormone Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 201000007386 factor VII deficiency Diseases 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108010081934 follitropin beta Proteins 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229940064298 pregnyl Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 108010055450 with HCG C-terminal peptide human follicle stimulating hormone Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
化合物# | A | B | C | D | E | F | G | H | I | J |
recFSH | 50IU | 50IU | 50IU | 50IU | 50IU | 600IU | 600IU | 600IU | 600IU | 600IU |
蔗糖 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
柠檬酸钠二水合物 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 |
聚山梨醇酯-20 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
DL-甲硫氨酸 | - | 0.1 | 0.25 | 0.5 | 1.0 | - | 0.1 | 0.25 | 0.5 | 1.0 |
pH | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
加水至(ml) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
1个月8℃ | 1个月30℃ | 1个月40℃ | 2个月8℃ | 2个月30℃ | 2个月40℃ | |
A | 90 | 83 | 63 | 95 | 84 | 52 |
B | 86 | 82 | 68 | 95 | 87 | 60 |
C | 76 | 72 | 67 | 83 | 89 | 69 |
D | 92 | 98 | 85 | 95 | 92 | 73 |
E | 97 | 83 | 73 | 100 | 83 | 72 |
F | 87 | 84 | 71 | 90 | 80 | 55 |
G | 97 | 98 | 84 | 87 | 85 | 67 |
H | 89 | 90 | 78 | 96 | 99 | 83 |
I | 99 | 85 | 75 | 96 | 88 | 73 |
J | 92 | 90 | 82 | 100 | 89 | 75 |
化合物# | A | B | C | D | E | F | G | H | I | J |
recFSH-CTP | 5μg | 5μg | 5μg | 5μg | 5μg | 30μg | 30μg | 30μg | 30μg | 30μg |
蔗糖 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
柠檬酸钠二水合物 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 |
聚山梨醇酯-20 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
DL-甲硫氨酸 | - | 0.1 | 0.25 | 0.5 | 1.0 | - | 0.1 | 0.25 | 0.5 | 1.0 |
pH | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
加水至(ml) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
2个月8℃ | 2个月20℃ | 2个月30℃ | 2个月40℃ | |
A | 89 | 87 | 75 | 50 |
B | 87 | 90 | 89 | 74 |
C | 93 | 95 | 88 | 66 |
D | 89 | - | 83 | 60 |
E | 103 | 101 | 97 | - |
F | 78 | 75 | 68 | 43 |
G | 84 | 90 | 89 | 70 |
H | 88 | 85 | 85 | 74 |
I | 92 | 92 | 90 | 74 |
J | 88 | 92 | 89 | 72 |
Claims (15)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97200099.6 | 1997-01-15 | ||
EP97200099 | 1997-01-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1191139A true CN1191139A (zh) | 1998-08-26 |
CN1165341C CN1165341C (zh) | 2004-09-08 |
Family
ID=8227932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB981041493A Expired - Lifetime CN1165341C (zh) | 1997-01-15 | 1998-01-13 | 含有促性腺素的液体制剂 |
Country Status (30)
Country | Link |
---|---|
US (1) | US5929028A (zh) |
EP (2) | EP1285665A1 (zh) |
JP (1) | JP4353549B2 (zh) |
KR (1) | KR100498531B1 (zh) |
CN (1) | CN1165341C (zh) |
AR (1) | AR011410A1 (zh) |
AT (1) | ATE237348T1 (zh) |
AU (1) | AU736339B2 (zh) |
BR (1) | BR9800323B1 (zh) |
CA (1) | CA2226803A1 (zh) |
CZ (1) | CZ297419B6 (zh) |
DE (2) | DE122010000011I1 (zh) |
DK (1) | DK0853945T3 (zh) |
ES (1) | ES2196474T3 (zh) |
FR (1) | FR10C0024I2 (zh) |
HK (1) | HK1010150A1 (zh) |
HU (1) | HU227154B1 (zh) |
ID (1) | ID19499A (zh) |
IL (1) | IL122732A0 (zh) |
LU (1) | LU91655I2 (zh) |
MX (1) | MX9800438A (zh) |
NO (3) | NO322509B1 (zh) |
NZ (1) | NZ329572A (zh) |
PL (1) | PL190103B1 (zh) |
PT (1) | PT853945E (zh) |
RU (1) | RU2203086C2 (zh) |
SA (1) | SA98181124B1 (zh) |
TR (1) | TR199800062A2 (zh) |
TW (1) | TW518235B (zh) |
ZA (1) | ZA9883B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100384468C (zh) * | 2001-08-30 | 2008-04-30 | 麒麟-安姆根有限公司 | L-甲硫氨酸在无hsa的制剂中用作nesp/epo的稳定剂 |
CN101347613B (zh) * | 2008-09-17 | 2011-10-26 | 上海天伟生物制药有限公司 | 几乎不含亚基的糖蛋白的组合物及其制备方法 |
CN102309745A (zh) * | 2008-09-17 | 2012-01-11 | 上海天伟生物制药有限公司 | 几乎不含亚基的糖蛋白的组合物 |
CN104010650A (zh) * | 2011-08-02 | 2014-08-27 | Opko生物科学有限公司 | 长效生长激素及其生产方法 |
CN104688679A (zh) * | 2008-02-08 | 2015-06-10 | 拉蒂奥法姆有限责任公司 | 促卵泡激素的液体制剂 |
CN112451652A (zh) * | 2020-12-07 | 2021-03-09 | 苏州智核生物医药科技有限公司 | 一种重组人促甲状腺素注射液 |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL140984A0 (en) * | 1998-07-23 | 2002-02-10 | Lilly Co Eli | Fsh and fsh variant formulations, products and methods |
US20030166525A1 (en) | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
JP2007204498A (ja) * | 1999-03-01 | 2007-08-16 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
JP2003504346A (ja) * | 1999-07-12 | 2003-02-04 | グランデイス・バイオテツク・ゲー・エム・ベー・ハー | 成長ホルモン製剤 |
PL207728B1 (pl) * | 2000-02-22 | 2011-01-31 | Serono Lab | Sposób oczyszczania LH z próbki, zastosowanie rekombinowanego hLH oraz kompozycja farmaceutyczna |
US7256184B2 (en) * | 2000-10-16 | 2007-08-14 | Rodriguez Victorio C | Treatment of aging disorders in humans |
AU2007200662A1 (en) * | 2001-08-30 | 2007-03-08 | Kirin-Amgen, Inc. | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
EP1346843A1 (en) * | 2002-03-22 | 2003-09-24 | Fuji Photo Film Co., Ltd. | Image forming method |
BRPI0409571B1 (pt) | 2003-03-04 | 2016-05-31 | Aspenbio Pharma Inc | método para manter uma ou mais gravidezes em um ou mais mamíferos |
MXPA05010635A (es) * | 2003-04-02 | 2005-12-12 | Ares Trading Sa | Formulaciones farmaceuticas liquidas de hormona estimulante de foliculos y hormona luteinizante junto con un surfactante no ionico. |
US20040248784A1 (en) | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
ES2414705T3 (es) * | 2003-06-20 | 2013-07-22 | Ares Trading S.A. | Formulaciones liofilizadas de FSH/LH |
JP4412989B2 (ja) * | 2003-12-15 | 2010-02-10 | 株式会社日立製作所 | 複数の記憶システムを有するデータ処理システム |
KR100587535B1 (ko) * | 2004-02-04 | 2006-06-08 | 충남대학교산학협력단 | 재조합 hFSH 유전자 및 이를 내장하는 발현용 벡터 |
TWI369401B (en) | 2005-07-05 | 2012-08-01 | Ares Trading Sa | Serum-free culture medium for the production of recombinant gonadotropins |
KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
WO2007056851A1 (en) * | 2005-11-17 | 2007-05-24 | Mount Sinai Hospital | Compositions and methods for enhancing ovulation inducing agents |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
CN101517883B (zh) * | 2006-09-25 | 2012-07-04 | 国立大学法人东京农工大学 | 超声波操作装置和微细管内检查系统 |
KR20080106636A (ko) * | 2007-06-04 | 2008-12-09 | 동아제약주식회사 | 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액 |
MX2009013886A (es) * | 2007-06-25 | 2010-01-27 | Amgen Inc | Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos. |
US8318457B2 (en) | 2007-06-28 | 2012-11-27 | Biogenerix Ag | FSH producing cell clone |
US8664369B2 (en) * | 2007-11-01 | 2014-03-04 | Merck Serono S.A. | LH liquid formulations |
TWI488640B (zh) * | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
US8329649B2 (en) | 2008-11-04 | 2012-12-11 | Aska Pharmaceutical Co., Ltd. | Aqueous composition containing follicle-stimulating hormone and histidine |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
EP2325194A1 (en) | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
WO2012127501A2 (en) * | 2011-03-11 | 2012-09-27 | Sanzyme Limited | Composition for improving endometrial thickness during ovarian stimulation |
WO2012127500A2 (en) * | 2011-03-11 | 2012-09-27 | Sanzyme Limited | Composition for spermatogenesis |
CA3163525A1 (en) | 2011-03-31 | 2012-10-04 | Ferring Bv. | Pharmaceutical preparation |
US8680086B2 (en) | 2011-04-15 | 2014-03-25 | Neuralight Hd, Llc | Methods for chronic pain management and treatment using HCG |
US20120265129A1 (en) | 2011-04-15 | 2012-10-18 | Neuralight Hd, Llc | Methods for Chronic Pain Management and Treatment using HCG |
RU2014103185A (ru) | 2011-07-18 | 2015-08-27 | Артс Байолоджикс А/С | Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием |
JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
US20150290292A1 (en) | 2012-10-18 | 2015-10-15 | Neuralight Hd, Llc | Treatment of Depression and PTSD |
EP3848386A1 (en) | 2012-11-20 | 2021-07-14 | OPKO Biologics Ltd. | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
JP6294868B2 (ja) | 2013-03-12 | 2018-03-14 | 大日本住友製薬株式会社 | 液体水性組成物 |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
EA201690626A1 (ru) | 2013-11-12 | 2016-09-30 | Кадила Хелзкэр Лимитед | Новый состав гонадотропинов |
PT3209319T (pt) * | 2014-10-21 | 2021-09-24 | Hexima Ltd | Um método de tratamento |
US10960058B2 (en) | 2015-06-19 | 2021-03-30 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
HUE064463T2 (hu) | 2016-07-11 | 2024-03-28 | Opko Biologics Ltd | Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások |
KR102444230B1 (ko) | 2016-09-13 | 2022-09-19 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
WO2020229699A1 (en) | 2019-05-16 | 2020-11-19 | Ceva Sante Animale | Compositions and methods for increasing reproduction performance in non human mammals using recombinant luteinizing hormone |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4357934A (en) * | 1980-07-23 | 1982-11-09 | The Curators Of The University Of Missouri | Method of treating male infertility |
US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
IT1206302B (it) * | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5338835A (en) * | 1989-02-21 | 1994-08-16 | Washington University | CTP-extended form of FSH |
DE69029799T2 (de) * | 1989-02-21 | 1997-05-28 | Washington University, St. Louis, Mo. | Modifizierte formen von fortpflanzungshormonen |
US5114948A (en) * | 1989-10-19 | 1992-05-19 | Eli Lilly And Company | Stabilized pergolide compositions |
IE64738B1 (en) * | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
US5384132A (en) * | 1990-03-20 | 1995-01-24 | Akzo N.V. | Stabilized gonadotropin containing preparations |
US5272135A (en) * | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
ATE173739T1 (de) * | 1992-04-30 | 1998-12-15 | Cor Therapeutics Inc | Stabile zusammensetzung von polypeptiden |
US5281198A (en) * | 1992-05-04 | 1994-01-25 | Habley Medical Technology Corporation | Pharmaceutical component-mixing delivery assembly |
KR100377967B1 (ko) * | 1995-03-21 | 2003-06-12 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | Hcg액상조성물 |
-
1997
- 1997-12-23 TW TW086119598A patent/TW518235B/zh not_active IP Right Cessation
- 1997-12-23 IL IL12273297A patent/IL122732A0/xx not_active IP Right Cessation
-
1998
- 1998-01-06 ZA ZA9883A patent/ZA9883B/xx unknown
- 1998-01-12 ID IDP980030A patent/ID19499A/id unknown
- 1998-01-13 DK DK98200068T patent/DK0853945T3/da active
- 1998-01-13 CN CNB981041493A patent/CN1165341C/zh not_active Expired - Lifetime
- 1998-01-13 NZ NZ329572A patent/NZ329572A/xx not_active IP Right Cessation
- 1998-01-13 EP EP02079923A patent/EP1285665A1/en not_active Withdrawn
- 1998-01-13 EP EP98200068A patent/EP0853945B1/en not_active Expired - Lifetime
- 1998-01-13 ES ES98200068T patent/ES2196474T3/es not_active Expired - Lifetime
- 1998-01-13 DE DE122010000011C patent/DE122010000011I1/de active Pending
- 1998-01-13 DE DE69813322T patent/DE69813322T2/de not_active Expired - Lifetime
- 1998-01-13 PT PT98200068T patent/PT853945E/pt unknown
- 1998-01-13 AT AT98200068T patent/ATE237348T1/de active
- 1998-01-14 HU HU9800056A patent/HU227154B1/hu active Protection Beyond IP Right Term
- 1998-01-14 CA CA002226803A patent/CA2226803A1/en not_active Abandoned
- 1998-01-14 PL PL98324279A patent/PL190103B1/pl unknown
- 1998-01-14 KR KR10-1998-0000785A patent/KR100498531B1/ko not_active IP Right Cessation
- 1998-01-14 NO NO19980177A patent/NO322509B1/no not_active IP Right Cessation
- 1998-01-14 JP JP00538998A patent/JP4353549B2/ja not_active Expired - Lifetime
- 1998-01-14 RU RU98100930/14A patent/RU2203086C2/ru active Protection Beyond IP Right Term
- 1998-01-14 MX MX9800438A patent/MX9800438A/es active IP Right Grant
- 1998-01-14 BR BRPI9800323-2A patent/BR9800323B1/pt not_active IP Right Cessation
- 1998-01-14 AR ARP980100152A patent/AR011410A1/es active IP Right Grant
- 1998-01-14 AU AU52059/98A patent/AU736339B2/en not_active Expired
- 1998-01-15 TR TR1998/00062A patent/TR199800062A2/xx unknown
- 1998-01-15 CZ CZ0013598A patent/CZ297419B6/cs not_active IP Right Cessation
- 1998-04-14 US US09/006,812 patent/US5929028A/en not_active Expired - Lifetime
- 1998-04-22 SA SA98181124A patent/SA98181124B1/ar unknown
- 1998-10-12 HK HK98111196A patent/HK1010150A1/xx not_active IP Right Cessation
-
2010
- 2010-02-24 LU LU91655C patent/LU91655I2/fr unknown
- 2010-04-16 FR FR10C0024C patent/FR10C0024I2/fr active Active
- 2010-06-07 NO NO2010013C patent/NO2010013I2/no not_active IP Right Cessation
-
2021
- 2021-01-12 NO NO2021001C patent/NO2021001I1/no unknown
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100384468C (zh) * | 2001-08-30 | 2008-04-30 | 麒麟-安姆根有限公司 | L-甲硫氨酸在无hsa的制剂中用作nesp/epo的稳定剂 |
CN104688679A (zh) * | 2008-02-08 | 2015-06-10 | 拉蒂奥法姆有限责任公司 | 促卵泡激素的液体制剂 |
CN101347613B (zh) * | 2008-09-17 | 2011-10-26 | 上海天伟生物制药有限公司 | 几乎不含亚基的糖蛋白的组合物及其制备方法 |
CN102309745A (zh) * | 2008-09-17 | 2012-01-11 | 上海天伟生物制药有限公司 | 几乎不含亚基的糖蛋白的组合物 |
CN102309745B (zh) * | 2008-09-17 | 2013-05-08 | 上海天伟生物制药有限公司 | 一种卵泡刺激素冻干针剂 |
CN104010650A (zh) * | 2011-08-02 | 2014-08-27 | Opko生物科学有限公司 | 长效生长激素及其生产方法 |
CN112451652A (zh) * | 2020-12-07 | 2021-03-09 | 苏州智核生物医药科技有限公司 | 一种重组人促甲状腺素注射液 |
CN114404575A (zh) * | 2020-12-07 | 2022-04-29 | 苏州智核生物医药科技有限公司 | 一种重组人促甲状腺素注射液 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1165341C (zh) | 含有促性腺素的液体制剂 | |
KR100221123B1 (ko) | 안정화된 고나도트로핀을 함유하는 제제 | |
RU2553375C2 (ru) | Жидкий состав фолликулостимулирующего гормона | |
JP3702313B2 (ja) | ゴナドトロピン含有薬剤組成物 | |
AU2004226666B2 (en) | Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant | |
US5384132A (en) | Stabilized gonadotropin containing preparations | |
AU2004248931B2 (en) | Freeze-dried FSH / LH formulations | |
US5270057A (en) | Stabilized gonadotropin containing preparations | |
JP5143784B2 (ja) | 糖タンパク質ホルモン組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ORGANON NV Free format text: FORMER OWNER: AKZO NOVEL N.V. CORP. Effective date: 20061229 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20061229 Address after: Holland Patentee after: N.V. ORGANON Address before: Holland Arnhem Patentee before: AKZO NOBEL N.V. |
|
C56 | Change in the name or address of the patentee |
Owner name: MSD OUSI CO., LTD. Free format text: FORMER NAME: ORGANON NV |
|
CP01 | Change in the name or title of a patent holder |
Address after: Dutch Oss Patentee after: N.V. Organon Address before: Dutch Oss Patentee before: N.V. ORGANON |
|
ASS | Succession or assignment of patent right |
Owner name: MERCK SHARP + DOHME CORP. Free format text: FORMER OWNER: ORGANON BIOLOGICAL NETHERLANDS CO., LTD. Effective date: 20131014 Owner name: ORGANON BIOLOGICAL NETHERLANDS CO., LTD. Free format text: FORMER OWNER: MSD OUSI CO., LTD. Effective date: 20131014 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20131014 Address after: Haarlem Patentee after: MERCK SHARP & DOHME B.V. Address before: Haarlem Patentee before: Organon biological science Holland Co.,Ltd. Effective date of registration: 20131014 Address after: Haarlem Patentee after: Organon biological science Holland Co.,Ltd. Address before: Holland Patentee before: N.V. Organon |
|
CX01 | Expiry of patent term |
Granted publication date: 20040908 |
|
CX01 | Expiry of patent term |